Takeda announces u.s. fda approval of gammagard liquid erc, the only ready-to-use liquid immunoglobulin therapy with low immunoglobulin a (iga) content1

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the u.s. food and drug administration (fda) has approved gammagard liquid erc [immune globulin infusion (human)] with less than or equal to 2 Μg/ml iga in a 10% solution, the only ready-to-use liquid immunoglobulin (ig) therapy with low immunoglobulin a (iga) content, as replacement therapy for people two years of age and older with primary immunodeficiency (pi). as a ready-to-use liquid, gammagard.
TAK Ratings Summary
TAK Quant Ranking